Daniel Bradbury

Dan is a co-founder and Executive Chairman of the Board of Directors. He also serves as the Managing Member of BioBrit, a life sciences consulting and investment firm. Prior to co-founding Equillium, he served as the President, Chief Executive Officer and Director of Amylin Pharmaceuticals, a biopharmaceutical company focused on metabolic diseases. During his 18-year tenure at Amylin, the company launched three first-in-class medicines, including the first once-a-week therapy to treat diabetes, and was listed on the Nasdaq 100. He served as Amylin’s Chief Executive Officer from March 2007 until its acquisition by Bristol-Myers Squibb Company in August 2012. Before joining Amylin, Dan worked in marketing and sales for 10 years at SmithKline Beecham Pharmaceuticals. He serves on the board of directors of Intercept Pharmaceuticals (NASDAQ: ICPT) and a number of private companies and philanthropic organizations.

Dan received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.